NASDAQ · STAAHealthcareOphthalmic Goods

Staar Surgical Co financials

$22.43+7.47%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

QuarterQ2 '26
Jul 3
Q1 '26
Apr 3
Q4 '25
Jan 2
Q3 '25
Sep 26
Q2 '25
Jun 27
Q1 '25
Mar 28
Q4 '24
Dec 27
Q3 '24
Sep 27
Q2 '24
Jun 28
Q1 '24
Mar 29
Q4 '23
Dec 29
Q3 '23
Sep 29
Revenue$93.5M$93.5M$57.8M$94.7M$44.3M$42.6M$49.0M$88.6M$99.0M$77.4M$76.3M$80.3M
Gross profit$69.7M$68.9M$43.7M$77.9M$32.8M$28.0M$31.6M$68.5M$78.4M$61.0M$60.7M$63.6M
Gross margin74.5%73.6%75.7%82.2%74.0%65.8%64.7%77.3%79.2%78.9%79.6%79.2%
Operating income$10.1M$8.0M-$22.8M$18.5M-$30.0M-$57.4M-$27.9M$5.7M$11.9M-$2.3M$10.4M$6.3M
Net income$8.1M$5.2M-$18.3M$8.9M-$16.8M-$54.2M-$34.2M$10.0M$7.4M-$3.3M$7.8M$4.8M
Net margin8.6%5.6%−31.7%9.4%−37.9%−127.3%−69.9%11.3%7.5%−4.3%10.2%6.0%
Diluted EPS$0.16$0.10$-0.37$0.18$-0.34$-1.10$-0.71$0.20$0.15$-0.07$0.16$0.10
EBITDA$13.4M$12.9M-$19.7M$20.5M-$22.6M-$32.3M-$25.5M$7.4M$13.4M-$1.0M$11.6M$7.6M
Operating cash flow$19.7M-$21.7M-$3.9M$2.7M-$27.2M-$5.7M$642.0K$3.8M-$10.4M$21.7M$32.0M-$6.0M
Free cash flow$19.2M-$22.1M-$5.6M$1.8M-$29.0M-$7.2M-$5.1M-$2.4M-$16.6M$16.5M$28.9M-$15.2M
Diluted shares51.5M50.9M48.9M50.5M49.5M49.3M48.1M49.7M49.8M48.9M49.3M49.4M

Balance sheet

Period endJul 3Apr 3Jan 2Sep 26Jun 27Mar 28
Cash & equivalents$148.6M$131.9M$153.2M$176.2M$167.1M$173.1M
Short-term investments$32.9M$32.0M$34.4M$16.5M$22.8M$49.6M
Total debt$0.00$0.00$0.00$0.00$0.00$0.00
Total assets$475.2M$451.1M$451.7M$456.4M$437.8M$457.4M
Total liabilities$109.8M$98.8M$107.5M$102.6M$101.2M$107.4M
Shareholders' equity$365.4M$352.4M$344.2M$353.8M$336.6M$350.0M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology